Navigation Links
S*BIO Announces US$5 Million Investment by Mitsui Ventures
Date:9/22/2010

SINGAPORE, Sept. 23 /PRNewswire/ -- S*BIO Pte Ltd today announced a US$5 million investment by Mitsui Ventures that will support the continued development of S*BIO's clinical programs.  

"Mitsui Ventures' financing commitment reflects the international investment community's strong interest in our track record in advancing multiple assets through clinical development and the quality of our various preclinical and clinical programs," said Dr. Jan-Anders Karlsson, CEO of S*BIO.  "The involvement of Mitsui Ventures broadens our investor base and also enhances the company's profile and standing in Japan and Asia."

This investment follows the recent patient enrolment completion of S*BIO's Phase 2 clinical trials with its orally-active JAK2 inhibitor, SB1518.  S*BIO's other lead compound SB939, a novel HDAC inhibitor is scheduled to enter Phase 2 Studies in Q3 2010.

Mr. Katsuhiko Oizumi, President and CEO of MVC Corporation (Mitsui Ventures), said, "S*BIO's cutting edge technology and the market potential of its drug candidates fits with our investment strategy to provide financing for programs that have distinctive and attractive features and can capture a significant portion of major markets."

Ms. Swee Yeok Chu, CEO of Bio*One Capital a subsidiary of EDBI, added, "We are pleased to have Mitsui Ventures as a co-investor to strengthen the collaborative opportunities which S*BIO presents to pharmaceutical partners particularly in Japan.  This financing comes at an exciting time for S*BIO when there has been significant progress made in the clinical advancement of the company's proprietary compounds and as S*BIO moves closer to the final stages of development with its anti-cancer agents."

About Mitsui VenturesMitsui Ventures is a venture investment arm of Mitsui & Co., Ltd. on a mission to invest in venture companies worldwide.  Mitsui Ventures consists of MVC Corporation, investing mainly in Japan, China
'/>"/>

SOURCE S*BIO
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
2. S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
3. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
4. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
5. S*BIO Completes US$26 Million Equity Financing
6. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
7. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
8. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
9. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
10. Metamark Genetics, Inc. Announces New Chief Scientific Officer
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Elsevier, a world-leading provider of scientific, technical and medical ... a recent study in Reproductive BioMedicine Online ... those with an abnormal chromosomal composition can be identified ... blastocysts, thereby classifying the risk of genetic abnormality without ... has undertaken a retrospective study, using their predictive model ...
(Date:5/17/2013)... PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability ,     New ... insect pressures , Syngenta unveiled ... celebration today at the company’s RTP Innovation Center. The ... allows company researchers to simulate any agricultural climate and ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... SAN JOSE, Calif. , May 17, 2013 ... an agreement has been reached with ... entire portfolio of anti-infective human monoclonal antibody (mAb) ... six anti-infective human mAb products for treatment of ... strains of Staphylococcus aureus , Pseudomonas ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... , Introduction ... used to display data from all SPEX instruments. DataMax can ... map displays multifiles or 3-D data, and looks much like a geographical ... X values are plotted on the horizontal axis, and z values are ...
... , ... The SPEX FLUOROLOG ... other accessories. The standard FLUOROLOG configuration has an R928P ... 850 nm. For near-IR fluores-cence measurements, an optional solid-state de-tector (DSS-IGA020L) ...
... , , ... Protein-containing plants are staples in the diets of all countries. The ability ... people have to have enough to eat before they can advance to higher ... the amount of rainfall, the occurrence of frost, wind erosion, etc., can be ...
Cached Biology Technology:Obtaining a contour map from multifiles or 3D data in DataMax 2Obtaining a contour map from multifiles or 3D data in DataMax 3Food science: increasing crop yields 2
(Date:5/17/2013)... MD The Federation of American Societies for Experimental ... National Institutes of Health (NIH) funding trends highlighting the ... support critical research. The FASEB analysis follows a May ... Collins, MD, PhD, who testified that the $1.6 billion ... sequestration is "having a substantial impact on the scientific ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Society for Developmental Biology (SDB) 72nd Annual ... These awards are meant to promote the entry ... into the mainstream of the basic science community ... at the SDB 2013 Annual Meeting. , Awards ...
(Date:5/16/2013)... Injectable nanoparticles developed at MIT may someday eliminate ... to constantly monitor their blood-sugar levels and inject ... to sense glucose levels in the body and ... thereby replacing the function of pancreatic islet cells, ... diabetes. Ultimately, this type of system could ensure ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
... WASHINGTONKrzysztof Matyjaszewski, the J.C. Warner Professor of the ... University, will receive the 2009 Presidential Green Chemistry ... at a ceremony at 5:30 p.m., Monday, June ... the second Carnegie Mellon professor to receive the ...
... HOUSTON (June 21, 2009) Rearrangements of all ... glitch in DNA copying that occurs when the process stalls ... genetic template, duplicating and even triplicating genes or just shuffling ... from Baylor College of Medicine in a recent report in ...
... ,Market Leader, in One-Time Passwords for Highest Ability to Execute ... RSA, The Security Division of EMC (NYSE: ... entitled, An Overview and Competitive Analysis for the One ... leader in one-time password (OTP) technology for strong authentication based ...
Cached Biology News:Carnegie Mellon's Kris Matyjaszewski recieves EPA's Presidential Green Chemistry Challenge Award 2Carnegie Mellon's Kris Matyjaszewski recieves EPA's Presidential Green Chemistry Challenge Award 3DNA template could explain evolutionary shifts 2DNA template could explain evolutionary shifts 3RSA Designated as the Leader in One-Time Password Market by Frost & Sullivan 2RSA Designated as the Leader in One-Time Password Market by Frost & Sullivan 3RSA Designated as the Leader in One-Time Password Market by Frost & Sullivan 4
XPC Immunogen: XPC (NP_004619, 141 a.a. ~ 251 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Biology Products: